Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases
BACKGROUND/AIMS: Based on our favorable results of interleukin-2-based immuno-chemotherapy in the treatment of unresectable liver metastases from colorectal cancer, we utilized this therapy for the prevention of liver recurrence after liver resection.
MATERIALS AND METHODS: Eighteen patients with colon cancer metastatic to the liver underwent successful hepatic resection and adjuvant immunochemotherapy that included hepatic arterial infusion of interleukin-2 and mitomycin C, 5-fluorouracil. The regimen consisted of weekly interleukin-2 (1.4-2x 10(6) units), 5-fluorouracil (250 mg) by 2-hour infusion and bolus mitomycin C (4 mg) for 6 months.
RESULTS: Fourteen of 18 patients are alive and disease-free with a median postoperative follow-up of 28.5 months. Recurrent cancer has developed in 4 of the 18 patients (22%). The site of first recurrence was the lung in three patients (17%) and the pelvis in one (6%); no patients recurred in the liver.
CONCLUSIONS: We recommend this adjuvant immuno-chemotherapy for the prevention of liver recurrence after curative resection of colorectal liver metastases.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
1996 |
|---|---|
| Erschienen: |
1996 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:43 |
|---|---|
| Enthalten in: |
Hepato-gastroenterology - 43(1996), 9 vom: 20. Mai, Seite 688-91 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Okuno, K [VerfasserIn] |
|---|
| Themen: |
50SG953SK6 |
|---|
| Anmerkungen: |
Date Completed 14.01.1997 Date Revised 21.11.2013 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM087705990 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM087705990 | ||
| 003 | DE-627 | ||
| 005 | 20231222072316.0 | ||
| 007 | tu | ||
| 008 | 231222s1996 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0293.xml |
| 035 | |a (DE-627)NLM087705990 | ||
| 035 | |a (NLM)8799416 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Okuno, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Adjuvant hepatic arterial IL-2 and MMC, 5-FU after curative resection of colorectal liver metastases |
| 264 | 1 | |c 1996 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 14.01.1997 | ||
| 500 | |a Date Revised 21.11.2013 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND/AIMS: Based on our favorable results of interleukin-2-based immuno-chemotherapy in the treatment of unresectable liver metastases from colorectal cancer, we utilized this therapy for the prevention of liver recurrence after liver resection | ||
| 520 | |a MATERIALS AND METHODS: Eighteen patients with colon cancer metastatic to the liver underwent successful hepatic resection and adjuvant immunochemotherapy that included hepatic arterial infusion of interleukin-2 and mitomycin C, 5-fluorouracil. The regimen consisted of weekly interleukin-2 (1.4-2x 10(6) units), 5-fluorouracil (250 mg) by 2-hour infusion and bolus mitomycin C (4 mg) for 6 months | ||
| 520 | |a RESULTS: Fourteen of 18 patients are alive and disease-free with a median postoperative follow-up of 28.5 months. Recurrent cancer has developed in 4 of the 18 patients (22%). The site of first recurrence was the lung in three patients (17%) and the pelvis in one (6%); no patients recurred in the liver | ||
| 520 | |a CONCLUSIONS: We recommend this adjuvant immuno-chemotherapy for the prevention of liver recurrence after curative resection of colorectal liver metastases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 650 | 7 | |a Antimetabolites, Antineoplastic |2 NLM | |
| 650 | 7 | |a Interleukin-2 |2 NLM | |
| 650 | 7 | |a Mitomycin |2 NLM | |
| 650 | 7 | |a 50SG953SK6 |2 NLM | |
| 650 | 7 | |a Fluorouracil |2 NLM | |
| 650 | 7 | |a U3P01618RT |2 NLM | |
| 700 | 1 | |a Shigeoka, H |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Y S |e verfasserin |4 aut | |
| 700 | 1 | |a Son, E |e verfasserin |4 aut | |
| 700 | 1 | |a Kayama, H |e verfasserin |4 aut | |
| 700 | 1 | |a Nakai, T |e verfasserin |4 aut | |
| 700 | 1 | |a Koh, K |e verfasserin |4 aut | |
| 700 | 1 | |a Yasutomi, M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepato-gastroenterology |d 1993 |g 43(1996), 9 vom: 20. Mai, Seite 688-91 |w (DE-627)NLM012633151 |x 0172-6390 |7 nnns |
| 773 | 1 | 8 | |g volume:43 |g year:1996 |g number:9 |g day:20 |g month:05 |g pages:688-91 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 43 |j 1996 |e 9 |b 20 |c 05 |h 688-91 | ||